A link between a hemostatic disorder and preterm PROM: A role for tissue factor and tissue factor pathway inhibitor

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 21, Issue 10, 2008, Pages 732-744

  Erez, Offer ^a,b,f   Espinoza, Jimmy ^a,b   Chaiworapongsa, Tinnakorn ^a,b   Gotsch, Francesca ^a   Kusanovic, Juan Pedro ^a,b   Than, Nandor Gabor ^a   Mazaki Tovi, Shali ^a,b   Vaisbuch, Edi ^a,b   Papp, Zoltan ^c   Yoon, Bo Hyun ^d   Mi Han, Yu ^a   Hoppensteadt, Debra ^e   Fareed, Jawed ^e   Hassan, Sonia S ^a,b   Romero, Roberto ^a,b,f  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d Seoul National University College of Medicine   (South Korea)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

Author keywords

Coagulation; Inflammation; Pregnancy; Prelabor rupture of membranes; Prematurity; Preterm delivery; Thrombin; Thrombosis

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AMNIONITIS; ARTICLE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INFLAMMATION; MAJOR CLINICAL STUDY; NONPARAMETRIC TEST; PREMATURE FETUS MEMBRANE RUPTURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VAGINA BLEEDING;

AMNIOTIC FLUID; CHORIOAMNIONITIS; CROSS-SECTIONAL STUDIES; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; GESTATIONAL AGE; HEMOSTATIC DISORDERS; HUMANS; LIPOPROTEINS; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY COMPLICATIONS, INFECTIOUS; THROMBOPLASTIN; UTERINE HEMORRHAGE;

EID: 56549091548     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050802361807     Document Type: Article

References (119)

1. Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rotmensch S, Thaler HT, Romero R. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol 2002;187:1137-1142.
2. Arias F, Victoria A, Cho K, Kraus F. Placental histology and clinical characteristics of patients with preterm premature rupture of membranes. Obstet Gynecol 1997;89:265-271.
3. Chaiworapongsa T, Espinoza J, Yoshimatsu J, Kim YM, Bujold E, Edwin S, Yoon BH, Romero R. Activation of coagulation system in preterm labor and preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002;11:368-373.
4. Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ. Plasma levels of thrombin-antithrombin complexes predict preterm premature rupture of the fetal membranes. J Matern Fetal Med 2001;10:297-300.
5. Lockwood CJ, Toti P, Arcuri F, Paidas M, Buchwalder L, Krikun G, Schatz F. Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin-enhanced interleukin-8 expression in term decidua. Am J Pathol 2005;167:1443-1449.
6. Gomez R, Romero R, Nien JK, Medina L, Carstens M, Kim YM, Chaiworapongsa T, Espinoza J, Gonzalez R. Idiopathic vaginal bleeding during pregnancy as the only clinical manifestation of intrauterine infection. J Matern Fetal Neonatal Med 2005;18:31-37.
7. Gomez R, Athayde N, Pacora P, Mazor M, Yoon BH, Romero R. Increased thrombin in intrauterine inflammation. Am J Obstet Gynecol 1998;178:S62.
8. Gervasi MT, Chaiworapongsa T, Naccasha N, Pacora P, Berman S, Maymon E, Kim JC, Kim YM, Yoshimatsu J, Espinoza J, et al. Maternal intravascular inflammation in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2002;11:171-175.
9. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006;32:11-23.
10. Mackenzie AP, Schatz F, Krikun G, Funai EF, Kadner S, Lockwood CJ. Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin enhanced decidual matrix metalloproteinase-3 (stromelysin-1) expression. Am J Obstet Gynecol 2004;191:1996-2001.
11. Rosen T, Schatz F, Kuczynski E, Lam H, Koo AB, Lockwood CJ. Thrombin-enhanced matrix metalloproteinase-1 expression: a mechanism linking placental abruption with premature rupture of the membranes. J Matern Fetal Neonatal Med 2002;11:11-17.
12. Elovitz MA, Ascher-Landsberg J, Saunders T, Phillippe M. The mechanisms underlying the stimulatory effects of thrombin on myometrial smooth muscle. Am J Obstet Gynecol 2000;183:674-681.
13. Elovitz MA, Saunders T, Ascher-Landsberg J, Phillippe M. Effects of thrombin on myometrial contractions in vitro and in vivo.Am J Obstet Gynecol 2000;183:799-804.
14. Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Am J Obstet Gynecol 2001;185:1059-1063.
15. Lockwood CJ, Krikun G, Schatz F. The decidua regulates hemostasis in human endometrium. Semin Reprod Endocrinol 1999;17:45-51.
16. Lockwood CJ, Krikun G, Schatz F. Decidual cell-expressed tissue factor maintains hemostasis in human endometrium. Ann NY Acad Sci 2001;943:77-88.
17. Lockwood CJ, Schatz F. A biological model for the regulation of peri-implantational hemostasis and menstruation. J Soc Gynecol Investig 1996;3:159-165.
18. Hahn L. On fibrinolysis and coagulation during parturition and menstruation. Acta Obstet Gynecol Scand Suppl 1974;28:7-40.
19. Major CA, de VM, Lewis DF, Morgan MA. Preterm premature rupture of membranes and abruptio placentae: is there an association between these pregnancy complications? Am J Obstet Gynecol 1995;172:672-676.
20. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335-343.
21. Laskowski M Jr, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980;49:593-626.
22. Sarig G, Blumenfeld Z, Leiba R, Lanir N, Brenner B. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost 2005;94:980-985.
23. Uszynski M, Zekanowska E, Uszynski W, Kuczynski J. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic fluid and blood plasma: implications for the mechanism of amniotic fluid embolism. Eur J Obstet Gynecol Reprod Biol 2001;95:163-166.
24. Tay SP, Cheong SK, Boo NY. Circulating tissue factor, tissue factor pathway inhibitor and D-dimer in umbilical cord blood of normal term neonates and adult plasma. Blood Coagul Fibrinolysis 2003;14:125-129.
25. Edstrom CS, Calhoun DA, Christensen RD. Expression of tissue factor pathway inhibitor in human fetal and placental tissues. Early Hum Dev 2000;59:77-84.
26. Hube F, Reverdiau P, Iochmann S, Trassard S, Thibault G, Gruel Y. Demonstration of a tissue factor pathway inhibitor 2 messenger RNA synthesis by pure villous cytotrophoblast cells isolated from term human placentas. Biol Reprod 2003;68:1888-1894.
27. Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 1998;18:40-46.
28. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994;91:3353-3357.
29. Udagawa K, Miyagi Y, Hirahara F, Miyagi E, Nagashima Y, Minaguchi H, Misugi K, Yasumitsu H, Miyazaki K. Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 1998;19:217-223.
30. Udagawa K, Yasumitsu H, Esaki M, Sawada H, Nagashima Y, Aoki I, Jin M, Miyagi E, Nakazawa T, Hirahara F, et al. Subcellular localization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts. Placenta 2002;23:145-153.
31. Kamei S, Kazama Y, Kuijper JL, Foster DC, Kisiel W. Genomic structure and promoter activity of the human tissue factor pathway inhibitor-2 gene. Biochim Biophys Acta 2001;1517:430-435.
32. Kisiel W, Sprecher CA, Foster DC. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. Blood 1994;84:4384-4385.
33. Butzow R, Virtanen I, Seppala M, Narvanen O, Stenman UH, Ristimaki A, Bohn H. Monoclonal antibodies reacting with placental protein 5: use in radioimmunoassay, Western blot analysis, and immunohistochemistry. J Lab Clin Med 1988;111:249-256.
34. Chand HS, Foster DC, Kisiel W. Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost 2005;94:1122-1130.
35. Seppala M, Wahlstrom T, Bohn H. Circulating levels and tissue localization of placental protein five (PP5) in pregnancy and trophoblastic disease: absence of PP5 expression in the malignant trophoblast. Int J Cancer 1979;24:6-10.
36. Than GN, Bohn H, Szabo DG. Advances in pregnancy - related protein research. Boca Raton, FL: CRC Press; 1993. pp 1-333.
37. Obiekwe BC, Chard T. Placental protein 5: circulating levels in twin pregnancy and some observations on the analysis of biochemical data from multiple pregnancy. Eur J Obstet Gynecol Reprod Biol 1981;12:135-141.
38. Obiekwe BC, Sooby J, Salem HT, Chard T. Placental protein 5: disappearance from the circulation after delivery. Eur J Obstet Gynecol Reprod Biol 1982;13:1-5.
39. Abdel Gader AM, Al-Mishari AA, Awadalla SA, Buyuomi NM, Khashoggi T, Al-Hakeem M. Total and free tissue factor pathway inhibitor in pregnancy hypertension. Int J Gynaecol Obstet 2006;95:248-253.
40. Bellart J, Gilabert R, Angles A, Piera V, Miralles RM, Monasterio J, Cabero L. Tissue factor levels and high ratio of fibrinopeptide A: D-dimer as a measure of endothelial procoagulant disorder in pre-eclampsia. Br J Obstet Gynaecol 1999;106:594-597.
41. Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999;78:191-197.
42. Di Paolo S, Volpe P, Grandaliano G, Stallone G, Schena A, Greco P, Resta L, Selvaggi L, Cincione R, Schena FP, et al. Increased placental expression of tissue factor is associated with abnormal uterine and umbilical Doppler waveforms in severe preeclampsia with fetal growth restriction. J Nephrol 2003;16:650-657.
43. Aharon A, Lanir N, Drugan A, Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J Thromb Haemost 2005;3:2355-2357.
44. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163-168.
45. Redline RW, Heller D, Keating S, Kingdom J. Placental diagnostic criteria and clinical correlation - a workshop report. Placenta 2005; 26 (Suppl A):S114-S117.
46. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van VI, Demunck H, Kasper M, Breier G, Evrard P, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73-75.
47. Erlich J, Parry GC, Fearns C, Muller M, Carmeliet P, Luther T, Mackman N. Tissue factor is required for uterine hemostasis and maintenance of the placental labyrinth during gestation. Proc Natl Acad Sci USA 1999;96:8138-8143.
48. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88:1583-1587.
49. Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmback K, Danton MJ, Colbert MC, Witte DP, Fujikawa K, Davie EW, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996;93:6258-6263.
50. Lockwood CJ, Krikun G, Papp C, Toth-Pal E, Markiewicz L, Wang EY, Kerenyi T, Zhou X, Hausknecht V, Papp Z, et al. The role of progestationally regulated stromal cell tissue factor and type-1 plasminogen activator inhibitor (PAI-1) in endometrial hemostasis and menstruation. Ann NY Acad Sci 1994;734:57-79.
51. Lockwood CJ, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F. The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin Thromb Hemost 2007;33:111-117.
52. Kuczynski J, Uszynski W, Zekanowska E, Soszka T, Uszynski M. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in the placenta and myometrium. Eur J Obstet Gynecol Reprod Biol 2002;105:15-19.
53. Creter D. Amnioplastin: new reagent for coagulation tests. Lancet 1977;2:251.
54. Omsjo IH, Oian P, Maltau JM, Osterud B. Thromboplastin activity in amniotic fluid. Gynecol Obstet Invest 1985;19:1-5.
55. Lockwood CJ, Bach R, Guha A, Zhou XD, Miller WA, Nemerson Y. Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am J Obstet Gynecol 1991;165:1335-1341.
56. Holmes VA, Wallace JM. Haemostasis in normal pregnancy: a balancing act? Biochem Soc Trans 2005;33:428-332.
57. Bellart J, Gilabert R, Miralles RM, Monasterio J, Cabero L. Endothelial cell markers and fibrinopeptide A to D-dimer ratio as a measure of coagulation and fibrinolysis balance in normal pregnancy. Gynecol Obstet Invest 1998;46:17-21.
58. Oian P, Omsjo I, Maltau JM, Osterud B. Increased sensitivity to thromboplastin synthesis in blood monocytes from pre-eclamptic patients. Br J Obstet Gynaecol 1985;92:511-517.
59. Holmes VA, Wallace JM, Gilmore WS, McFaul P, Alexander HD. Tissue factor expression on monocyte subpopulations during normal pregnancy. Thromb Haemost 2002;87:953-958.
60. Stephenson CD, Lockwood CJ, Ma Y, Guller S. Thrombin-dependent regulation of matrix metalloproteinase (MMP)- 9 levels in human fetal membranes. J Matern Fetal Neonatal Med 2005;18:17-22.
61. Arias F, Rodriquez L, Rayne SC, Kraus FT. Maternal placental vasculopathy and infection: two distinct subgroups among patients with preterm labor and preterm ruptured membranes. Am J Obstet Gynecol 1993;168:585-591.
62. Schatz F, Krikun G, Caze R, Rahman M, Lockwood CJ. Progestin-regulated expression of tissue factor in decidual cells: implications in endometrial hemostasis, menstruation and angiogenesis. Steroids 2003;68:849-860.
63. Romero R, Gonçalves LF, Chaiworapongsa T, Kusanovic JP, Espinoza J. Mechanisms of preterm labor and preterm premature rupture of the membranes. In: Kurjak A, Chervenak F, editors. Textbook of perinatal medicine, 2nd edn. Taylor and Francis, 2006. pp 1379-1393.
64. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-430.
65. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005;15:254-259.
66. Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006;32:33-39.
67. Haas SL, Jesnowski R, Steiner M, Hummel F, Ringel J, Burstein C, Nizze H, Liebe S, Lohr JM. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol 2006;12:4843-4849.
68. Sawa H, Ueda T, Takeyama Y, Yasuda T, Matsumura N, Nakajima T, Ajiki T, Fujino Y, Suzuki Y, Kuroda Y. Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J Gastroenterol 2006;41:575-581.
69. Naumnik B, Borawski J, Chyczewski L, Pawlak K, Mysliwiec M. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis - immunostaining vs. plasma and urinary levels. Nephrol Dial Transplant 2006;21:3450-3457.
70. Roldan V, Marin F, Blann A. Soluble E-selectin, interleukin-6 and tissue factor in two cases of meningococcal septicaemia. Blood Coagul Fibrinolysis 2004;15:179-182.
71. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005;105:2764-2770.
72. Osterud B. Cellular interactions in tissue factor expression by blood monocytes. Blood Coagul Fibrinolysis 1995;6(Suppl 1):S20-S25.
73. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975;30:311-316.
74. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997;89:3270-3276.
75. Egorina EM, Sovershaev MA, Bjorkoy G, Gruber FX, Olsen JO, Parhami-Seren B, Mann KG, Osterud B. Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability. Arterioscler Thromb Vasc Biol 2005;25:1493-1498.
76. Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002;100:2787-2792.
77. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004;104:3190-3197.
78. Balasubramanian V, Vele O, Nemerson Y. Local shear conditions and platelet aggregates regulate the incorporation and activity of circulating tissue factor in ex vivo thrombi. Thromb Haemost 2002;88:822-826.
79. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995;73:10-14.
80. Rauch U, Nemerson Y. Circulating tissue factor and thrombosis. Curr Opin Hematol 2000;7:273-277.
81. Westmuckett AD, Lupu C, Goulding DA, Das S, Kakkar VV, Lupu F. In situ analysis of tissue factor-dependent thrombin generation in human atherosclerotic vessels. Thromb Haemost 2000;84:904-911.
82. Campo G, Valgimigli M, Ferraresi P, Malagutti P, Baroni M, Arcozzi C, Gemmati D, Percoco G, Parrinello G, Ferrari R, et al. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol 2006;26:2800-2806.
83. Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Munzel T, Peetz D, Nicaud V, et al. Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost 2007;5:475-482.
84. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520.
85. Broze GJ Jr. Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-7546.
86. Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro - modulatory action of glycosaminoglycans. Thromb Res 1994;75:609-616.
87. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-393.
88. Butzow R, Alfthan H, Stenman UH, Suikkari AM, Bohn H, Seppala M. Immunofluorometric demonstration and quantification of placental protein 5 in the absence of pregnancy. Clin Chem 1988;34:1591-1593.
89. Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996;35:266-272.
90. Rao CN, Peavey CL, Liu YY, Lapiere JC, Woodley DT. Partial characterization of matrix-associated serine protease inhibitors from human skin cells. J Invest Dermatol 1995;104:379-383.
91. Rao CN, Liu YY, Peavey CL, Woodley DT. Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys 1995;317:311-314.
92. Rao CN, Gomez DE, Woodley DT, Thorgeirsson UP. Partial characterization of novel serine proteinase inhibitors from human umbilical vein endothelial cells. Arch Biochem Biophys 1995;319:55-62.
93. Rao CN, Reddy P, Liu Y, O'Toole E, Reeder D, Foster DC, Kisiel W, Woodley DT. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys 1996;335:82-92.
94. Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun 1999;255:94-98.
95. Li Y, Rodriquez M, Spencer FA, Becker RC. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. J Thromb Thrombolysis 2002;14:123-129.
96. Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro.Thromb Haemost 2000;83:937-943.
97. Menabawey M, Silman R, Rice A, Chard T. Dramatic increase of placental protein 5 levels following injection of small doses of heparin. Br J Obstet Gynaecol 1985;92:207-210.
98. Meisser A, Bischof P, Bohn H. Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen. Arch Gynecol 1985;236:197-201.
99. Nisbet AD, Brenner RD, Horne CH, Bohn H. Placental protein 5 (PP5) in pregnancy and malignant disease: the influence of heparin binding. Clin Chim Acta 1982;119:21-29.
100. Jones GR, Davey MW, Sinosich M, Grudzinskas JG. Specific interaction between placental protein 5 and heparin. Clin Chim Acta 1981;110:65-70.
101. Jeske W, Fareed J. Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. Semin Thromb Hemost 2004;30 (Suppl 1):41-47.
102. Kemme MJ, Burggraaf J, Schoemaker RC, Kluft C, Cohen AF. Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. Br J Clin Pharmacol 2002;54:627-634.
103. Kaiser B, Hoppensteadt DA, Fareed J. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opin Investig Drugs 2001;10:1925-1935.
104. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000;30 (Suppl 2):48-56.
105. Kaiser B, Glusa E, Hoppensteadt DA, Breddin HK, Amiral J, Fareed J. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans. Blood Coagul Fibrinolysis 1998;9:517-523.
106. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Bendz B, Ostergaard P, Nordoy A. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 1998;101:638-646.
107. Jeske W, Hoppensteadt D, Klauser R, Kammereit A, Eckenberger P, Haas S, Wyld P, Fareed J. Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels. Blood Coagul Fibrinolysis 1995;6:119-124.
108. Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 1994;33:12686-12694.
109. Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993;268:26950-26955.
110. Ostergaard P, Nordfang O, Petersen LC, Valentin S, Kristensen H. Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations. Haemostasis 1993;23 (Suppl 1):107-111.
111. Wun TC. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 1992;79:430-438.
112. Lindahl AK, Abildgaard U, Larsen ML, Aamodt LM, Nordfang O, Beck TC. Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res Suppl 1991;14:39-48.
113. Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze GJ Jr. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 1993;4:661-669.
114. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-112.
115. Dahm A, Van H, V, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387-4392.
116. Rogolino A, Coccia ME, Fedi S, Gori AM, Cellai AP, Scarselli GF, Prisco D, Abbate R. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis 2003;14:277-282.
117. Gardiner C, Cohen H, Austin SK, Machin SJ, Mackie IJ. Pregnancy loss, tissue factor pathway inhibitor deficiency and resistance to activated protein C. J Thromb Haemost 2006;4:2724-2726.
118. Ogawa M, Yanoma S, Nagashima Y, Okamoto N, Ishikawa H, Haruki A, Miyagi E, Takahashi T, Hirahara F, Miyagi Y. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta 2007;28:224-232.
119. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1997;55:169-174.